BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37376789)

  • 21. Complete response after autologous stem cell transplant in multiple myeloma.
    Kumar L; Iqbal N; Mookerjee A; Verma RK; Sharma OD; Batra A; Pramanik R; Gupta R
    Cancer Med; 2014 Aug; 3(4):939-46. PubMed ID: 24777883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation.
    Cordas Dos Santos DM; Saliba RM; Patel R; Bashir Q; Saini N; Hosing C; Kebriaei P; Khouri IF; Nieto Y; Popat U; Ahmed H; Lee HC; Manasanch EE; Patel KK; Thomas SK; Weber DM; Orlowski RZ; Champlin RE; Qazilbash MH
    Biol Blood Marrow Transplant; 2020 Jun; 26(6):1077-1083. PubMed ID: 31786242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis.
    Varma A; Sui D; Milton DR; Tang G; Saini N; Hasan O; Mukherjee A; Joseph JJ; Bashir Q; Rondon G; Srour S; Popat UR; Hosing CM; Nieto Y; Kebriaei P; Alousi AM; Ahmed S; Mehta R; Khouri IF; Ahmed H; Iyer S; Weber DM; Thomas SK; Manasanch E; Lee HC; Patel K; Ciurea SO; Shpall EJ; Orlowski RZ; Champlin RE; Qazilbash MH
    Biol Blood Marrow Transplant; 2020 Apr; 26(4):665-671. PubMed ID: 31881283
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma.
    El-Cheikh J; Crocchiolo R; Furst S; Stoppa AM; Ladaique P; Faucher C; Calmels B; Lemarie C; De Colella JM; Granata A; Coso D; Bouabdallah R; Chabannon C; Blaise D
    Am J Hematol; 2013 May; 88(5):370-4. PubMed ID: 23460414
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma.
    Afrough A; Alsfeld LC; Milton DR; Delgado R; Popat UR; Nieto Y; Kebriaei P; Oran B; Saini N; Srour S; Hosing C; Cheema FH; Ahmed S; Manasanch EE; Lee HC; Kaufman GP; Patel KK; Weber DM; Orlowski RZ; Pinnix CC; Dabaja BS; Thomas SK; Champlin RE; Shpall EJ; Qazilbash MH; Bashir Q
    Transplant Cell Ther; 2023 Apr; 29(4):264.e1-264.e9. PubMed ID: 35605883
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience.
    Pasvolsky O; Milton DR; Masood A; Sami SS; Tanner MR; Bashir Q; Srour S; Saini N; Lin P; Ramdial J; Nieto Y; Saeed A; Lee HC; Patel KK; Kebriaei P; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
    Am J Hematol; 2023 Oct; 98(10):1571-1578. PubMed ID: 37461327
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation.
    Jacobs RW; Saliba RM; Sasaki K; Farhan S; Armas A; Shah ND; Bashir Q; Qureshi S; Rondon G; Hosing C; Popat U; Parmar S; Shah JJ; Wang M; Weber DM; Thomas SK; Orlowski RZ; Champlin RE; Qazilbash MH
    Clin Lymphoma Myeloma Leuk; 2016 Jan; 16(1):36-42. PubMed ID: 26702475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
    Huang WY; Zou DH; Liu W; An G; Xu Y; Sui WW; Deng SH; Li CW; Liu H; Li J; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):496-500. PubMed ID: 30032568
    [No Abstract]   [Full Text] [Related]  

  • 29. Targeting complete response with upfront bortezomib consolidation versus observation after the achievement of complete response following autologous transplantation for multiple myeloma (TUBA study).
    Nakasone H; Terasako-Saito K; Hirano T; Wake A; Shimizu S; Kurita N; Yamazaki E; Usuki K; Akazawa K; Kanda J; Minauchi K; Yamamoto G; Tanimoto S; Kamoshita M; Yokoyama Y; Miyaoka E; Ota S; Kako S; Izutsu K; Kanda Y
    Hematol Oncol; 2018 Feb; 36(1):202-209. PubMed ID: 28681529
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early relapse post autologous transplant is a stronger predictor of survival compared with pretreatment patient factors in the novel agent era: analysis of the Singapore Multiple Myeloma Working Group.
    Ong SY; de Mel S; Chen YX; Ooi MG; Surendran S; Lin A; Koh LP; Linn YC; Ho AY; Hwang WY; Phipps C; Loh SM; Goh YT; Tan D; Chng WJ; Gopalakrishnan SK
    Bone Marrow Transplant; 2016 Jul; 51(7):933-7. PubMed ID: 26974274
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Post-relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation.
    Ahmed S; Zhao Q; Hanel W; Qazilbash MH; Patel K; Narra R; Kansagra A; Iqbal M; Awan FT; Christian B; Jaglowski SM; Kharfan-Dabaja MA; Hamadani M; Epperla N
    Hematol Oncol; 2022 Feb; 40(1):48-56. PubMed ID: 34763367
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Newly diagnosed multiple myeloma patients treated with tandem auto-allogeneic stem cell transplant have better overall survival with similar outcomes at time of relapse compared to patients who received autologous transplant only.
    LeBlanc R; Claveau JS; Ahmad I; Delisle JS; Bambace N; Bernard L; Cohen S; Kiss T; Lachance S; Landais S; Roy DC; Sauvageau G; Roy J
    Clin Transplant; 2020 Dec; 34(12):e14099. PubMed ID: 32981146
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.
    Krishnan A; Pasquini MC; Logan B; Stadtmauer EA; Vesole DH; Alyea E; Antin JH; Comenzo R; Goodman S; Hari P; Laport G; Qazilbash MH; Rowley S; Sahebi F; Somlo G; Vogl DT; Weisdorf D; Ewell M; Wu J; Geller NL; Horowitz MM; Giralt S; Maloney DG;
    Lancet Oncol; 2011 Dec; 12(13):1195-203. PubMed ID: 21962393
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation.
    Bock F; Lu G; Srour SA; Gaballa S; Lin HY; Baladandayuthapani V; Honhar M; Stich M; Shah ND; Bashir Q; Patel K; Popat U; Hosing C; Korbling M; Delgado R; Rondon G; Shah JJ; Thomas SK; Manasanch EE; Isermann B; Orlowski RZ; Champlin RE; Qazilbash MH
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2159-2164. PubMed ID: 27638366
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Efficacy and prognosis of newly diagnosed multiple myeloma patients treated with bortezomib, lenalidomide and dexamethasone].
    Xu JY; Yan WW; Fan HS; Liu JH; Du CX; Deng SH; Sui WW; Xu Y; Qiu LG; An G
    Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(30):2338-2344. PubMed ID: 35970791
    [No Abstract]   [Full Text] [Related]  

  • 36. [Analysis of the efficacy and prognosis on first-line autologous hematopoietic stem cell transplantation of patients with multiple myeloma].
    Zou DH; Sui WW; Yi SH; An G; Xu Y; Li ZJ; Li CW; Qi JY; Zhao YZ; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2013 Apr; 34(4):299-303. PubMed ID: 23668200
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Autologous stem cell transplantation for multiple myeloma: Long-term results.
    Kumar L; Boya RR; Pai R; Harish P; Mookerjee A; Sainath B; Patekar MB; Sahoo RK; Malik PS; Sharma OD; Gupta R
    Natl Med J India; 2016; 29(4):192-199. PubMed ID: 28050994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.
    Varma A; Biritxinaga L; Saliba RM; Stich M; Jauch SF; Afrough A; Honhar M; Popat UR; Shafi MA; Shah N; Bashir Q; Dinh Y; Hosing C; Champlin RE; Qazilbash MH
    Biol Blood Marrow Transplant; 2017 Apr; 23(4):581-587. PubMed ID: 28063964
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical characteristics and prognosis of patients with newly-diagnosed multiple myeloma with t(11;14)].
    Wang Y; Liu YF; Tao Y; Jin SW; Mi JQ
    Zhonghua Yi Xue Za Zhi; 2022 Sep; 102(36):2868-2873. PubMed ID: 36153872
    [No Abstract]   [Full Text] [Related]  

  • 40. Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma.
    Lemieux C; Muffly LS; Rezvani A; Lowsky R; Iberri DJ; Craig JK; Frank MJ; Johnston LJ; Liedtke M; Negrin R; Weng WK; Meyer E; Shizuru J; Shiraz P; Arai S; Miklos DB; Sidana S
    Bone Marrow Transplant; 2021 Feb; 56(2):368-375. PubMed ID: 32782351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.